Stock INTS INTENSITY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Delayed Nasdaq
Other stock markets
 09:46:33 22/05/2024 pm IST 		5-day change 1st Jan Change
4.99 USD +3.10% Intraday chart for Intensity Therapeutics, Inc. +3.31% -41.77%
15/05 Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors CI
10/05 Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
PR
Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors
CI
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe
AQ
Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK
CI
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial
MT
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
PR
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
CI
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Intensity Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
PU
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors
CI
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
PR
Portage biotech completes monetization of intensity therapeutics shares
AQ
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
AQ
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
PR
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
PR
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study
DJ
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
PR
Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INTS Stock
  4. News Intensity Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW